‘Next generation sequencing’ technology in routine analysis in Belgian healthcare system

Program

10.00 - 10.15 Welcome
10.15 - 10.25 Opening by Minister of Public Health Maggie De Block
10.30 - 12.30 Introduction of Next-Generation-Sequencing technology in (hemato)-oncology in the Belgian healthcare system
12.30 - 13.30 Lunch
13.30 - 16.00 Genomics in oncology and hemato-oncology: opportunities & challenges
4.00 - 5.30 PM Reception
NEXT GENERATION SEQUENCING GENE PANELS FOR TARGETED THERAPY IN ONCOLOGY AND HAEMATO-ONCOLOGY

MARC VAN DEN BULCKE, LORENA SAN MIGUEL, ROBERTO SALGADO, ELS DE QUECKER, HARLINDE DE SCHUTTER, ANOUK WAEYTENS, PETER VAN DEN BERGHE, SABINE TEJPAR, JEROEN VAN HOUDT, STEVEN VAN LAERE, BRIGITTE MAES, FRANK HULSTAERT

19 March 2015
Genomics in 21st century
Roadmap 2016-2020 for ‘NGS in routine analysis in oncology and haemato-oncology’

1. Organisation:
   - Expert WG on clinical utility of somatic mutations in oncology/haemato-oncology
   - Linkage CTG-TGR (drugs Φ tests)

2. Quality:
   - NGS guidelines, checklist and NGS genepanel
   - Real-life pilot study
     - Benchmarking test
     - Real-life pilot study

3. Registration, monitoring, evaluation (incl. cost):
   - Data management (actionable mutations, reimbursement, register)

4. Ethics, Legal impact:
   - Informed Consent (ethical and legal concerns)

5. Education and training
“Commission of Personalized Medicine”

Symposium NGS in (hemato) oncology
Marc Van den Bulcke
WIV-Kankercentrum
“Commission on Personalized Medicine”
(December 2015)
**General aim:**
Advisory board on clinical utility of ‘omics’ in oncology and haemato-oncology

**Principle tasks:**
- Develop a methodology to assess the clinical utility of novel somatic mutations
- Assess novel somatic mutations to be retained in reimbursed NGS gene panels, including registration
- Assess novel ‘omics’ technology for application in oncology
- Present evidence-based advise to officials
Organisation:

- Secretariat: Cancer Centre (WIV-ISP)
- Include representatives of all professional organisations directly involved in DNA profiling
- Working groups by tumour type or research issue/topic
- Regular ‘face to face’ meetings
- Seek international embedding
Organisation: general view

- Cancer Centre (CC)
- Management Board (MB)
- Scientific board (SB)
Management Board

Main role: Define the key activities – validate the outcomes

- Yearly planning key initiatives/scope
- Validation of outcomes/deliverables
- Online database
- 2 MB meetings /year

Confidentiality and Conflict of interest statement
‘Management Board’

Members:

- Riziv – Directie Farmaceutisch Beleid
- Riziv – Medische Directie
- FOD-VVVL
- platform CDx CTG/TGR
- College voor Oncologie
- College voor Genetica
- Commissie Pathologische Anatomie
- Commissie Klinische Biologie
- Kenniscentrum (KCE)
- Stichting Kankerregister
- FAGG
- BELAC
- WIV-ISP – afdeling ‘Kwaliteit van de Medische Labotaroria’
- WIV-ISP – afdeling ‘Healthdata’
Scientific Board

Who:
Belgian professionals and experts in the field of (haemato) oncology (preferentially with direct involvement in ‘personalized medicine’)

Role of the SB:
Provide advise on issues related to the clinical utility of somatic mutations in (haemato) oncology

Confidentiality and Conflict of interest statement
Scientific Board

How will we work?

- Organized in working groups around specific themes/issues

- Project-based approach (scope, methodology, standard report, SMART recommendations/measures)

- Limited number of participants in each WG (CV-based selection)

- Discussion on project progress/conclusions at regular plenary meetings
Commission Personalized Medicine

Proces within ‘ComPerMed’

Decision Bodies

Secr. CC

SB
PLAN

Proj 1
Proj 2
Proj 3
Proj 4
Workprogram 2016:

- NGS guidelines for (haemato) oncology (version 01 finalized)
- NGS genepanel for (haemato) oncology (at final stage for solid tumors)
- Support to NGS proficiency test (WIV-ISP Quality of Medical Labs and Kankercentrum) (invitation sent)
- Advise to /Interaction with CTG/TGR (ongoing)
- Establish mode of interaction with principal partners: Colleges of Oncology/Genetics, Commissions of Pathology/Clinical Biology, KCE, Cancer Registry, IMA, FAGG, WIV,... (ongoing)
- Develop methodology to assess clinical utility of somatic mutations in (haemato) oncology (ongoing)
- Guidelines/factsheets for the use of ‘omics’ in clinical practice (oncology, pathology, clinical biology, genetics) (started)
THANK YOU